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Alkaline sphingomyelinase (alk-SMase) is expressed in the intestine and human liver. It may inhibit colonic tumorigenesis, and loss of
function mutations have been identified in human colon cancer. The present study investigates its expression in human liver cancer. In
HepG2 liver cancer cells, RT–PCR identified three transcripts with 1.4, 1.2 and 0.4kb, respectively. The 1.4kb form is the wild-type
cDNA with five translated exons, the 1.2kb product lacks exon 4 and the 0.4kb form is a combination of exons 1 and 5. Genomic
sequence showed that these aberrant transcripts were products of alternative splicing. Transient expression of the 1.2kb form
showed no alk-SMase activity. In HepG2 cells, the alk-SMase activity is low in monolayer condition and increased with cell
polarisation. Coexistence of 1.4 and 1.2kb forms was also identified in one hepatoma biopsy. GenBank search identified a cDNA
clone from human liver tumour, which codes a protein containing full length of alk-SMase plus a 73-amino-acid tag at the N terminus.
The aberrant form was translated by an alternative starting codon upstream of the wild-type mRNA. Expression study showed that
linking the tag markedly reduced the enzyme activity. We also analysed human liver biopsy samples and found relatively low alk-
SMase activity in diseases with increased risk of liver tumorigenesis. In conclusion, expression of alk-SMase is changed in hepatic
tumorigenesis, resulting in loss or marked reduction of the enzyme function.
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Alkaline sphingomyelinase (alk-SMase), discovered in 1969,
hydrolyses sphingomyelin (SM) at optimal alkaline pH (Nilsson,
1969). Recent cloning studies showed that the enzyme shares no
similarities with other SMases but belongs to nucleotide pyro-
phosphatase/phosphodiesterase (NPP) family (Duan et al, 2003;
Wu et al, 2005a). Being a novel member of the NPP family, it is
also named NPP7 (Stefan et al, 2005). Alk-SMase is an ectoenzyme
with a signal peptide at the N terminus and a hydrophobic domain
at the C terminus. The N-terminal signal peptide is important for
transport of the enzyme to plasma membrane, whereas the C-
terminal hydrophobic domain is a signal anchor, which hooks the
enzyme to the surface of plasma membrane (Duan et al, 2003; Wu
et al, 2004b). The enzyme activity has been identified in the
intestinal tract of many species (Duan et al, 1996) and human bile
(Nyberg et al, 1996; Duan and Nilsson, 1997) but not in bile of
other species such as pig, rat, mouse, rabbit, sheep and baboon. In
agreement, northern blot has shown high levels of alk-SMase
mRNA in human liver (Duan et al, 2003) but not in rat liver (Wu
et al, 2005a). The enzyme appearing in the bile is believed to be
released from liver by bile salt (Duan et al, 1998). The enzyme in
the intestinal mucosa can also be released by trypsin, and the
cleaved enzyme has higher activity than the mucosal form (Wu
et al, 2004b).
Sphingomyelin metabolism generates both antiproliferative
molecules such as ceramide and sphingosine and proliferative
molecules such as sphingosine-1-phosphate, which are deeply
involved in development of many types of tumour (Ogretmen and
Hannun, 2004). Alk-SMase may function as a tumour suppressor
through three mechanisms, as recently reviewed (Duan, 2006).
First, it hydrolyses SM to generate ceramide, which inhibits cell
proliferation, and induces apoptosis mainly by dephosphorylation
and inactivation of many proliferative and antiapoptotic molecules
such as protein kinase B (Akt), protein kinase C, Bcl-2 and pRB
(Merrill et al, 1997; Pettus et al, 2002). Second, it hydrolyses and
inactivates platelet-activating factor, a potent proinflammatory
and proliferative molecule in the intestinal tract (Wu et al, 2006).
Finally, it degrades lysophosphatidylcholine by a phospholipase C
activity, thus reducing the formation of lysophosphatidic acid, a
potent factor that stimulates cell migration and angiogenesis
(Duan, 2006; Wu et al, 2006). We previously found that alk-SMase
activity was decreased in colonic adenomas and carcinomas, in
familial adenomatous polyposis and in longstanding ulcerative
colitis (Hertervig et al, 1997, 1999; Sjo ¨qvist et al, 2002). The
reduction was recently confirmed and the levels of alk-SMase in
the faeces have been considered as a potential marker for diagnosis
and prognosis of colon cancer (Di Marzio et al, 2005). The activity
reduction may be a consequence of genetic perturbations, as an
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sexon deletion that inactivates the enzyme has been found in HT29
colon cancer cells (Wu et al, 2004a).
While much attention has been paid to the enzyme in colon,
little is known about the changes of the enzyme in human liver, the
only organ except intestine that expresses alk-SMase (Duan et al,
1996, 2003; Wu et al, 2005a). Liver is important for generating
endogenous SM and regulating the SM levels in the plasma
(Nilsson and Duan, 2006), and previous studies have shown that
SM metabolism is implicated in liver diseases. Sphingomyelin has
been reported to protect hepatic cells against bile salts (Amigo
et al, 1999; Moschetta et al, 2003). Animals ingesting food
contaminated with mycotoxin fumonisin B, an inhibitor of
ceramide synthesis, have an increased risk of liver cancer (Merrill
et al, 1995; Gelderblom et al, 1996). Feeding animals with dietary
SM reduced the formation of liver enzyme-altered foci, a hepatic
marker of preneoplasia (Silins et al, 2003). Platelet-activating
factor, another substrate for alk-SMase, has important implica-
tions in carbon tetrachloride-induced liver cirrhosis (Yang et al,
2004), endotoxin- and alcohol-induced hepatic apoptosis and
necrosis (Murohisa et al, 2002), and liver metastasis of colon
cancer (Denizot et al, 2005). The present study for the first time
examines the expression of alk-SMase in human liver cancer cells
and diseased liver tissues. Our results indicate that the expression
of alk-SMase can be changed in human liver tumour and liver
diseases, resulting in marked reduction of the enzyme activity.
MATERIALS AND METHODS
Materials
HepG2 and COS-7 cells were purchased from American Tissue
Culture Collection. AK126250 clone was purchased from National
Institute of Technology and Evaluation (Chiba, Japan). Anti-
human alk-SMase antibody was generated by AgriSera AB
(Va ¨nna ¨s, Sweden) as described (Duan et al, 2003). Sphingomyelin
was labelled with [
14C-CH3]choline ([
14C-SM]) at Astra Zeneca,
(So ¨derta ¨lje, Sweden) (Stoffel, 1975). Plasmid pcDNA4/TO/myc-His
B, lipofectaminet 2000, Ready-To-Go RT–PCR beads, Quickprept
total RNA extraction kit, GFXt DNA purification kit, primers used
for PCR, and cell culture mediums were purchased from
Invitrogen (Stockholm, Sweden). RNA stabilisation reagent
(RNAlatert) was from Qiagen GmbH (Hilden, Germany). The
western blotting kit was from Amersham Biosciences (Uppsala,
Sweden). All other chemical agents were purchased from Sigma
Co. (Stockholm, Sweden). Human liver biopsy samples were
obtained from the University Hospitals in Lund and Malmo ¨, under
the ethical permission issued by the Regional Human Ethics
committee and the consents of each patient.
Methods
Cell culture HepG2 and COS-7 cells were cultured in DMEM
medium with 2mM glutamine, 4500mgl
 1 glucose, 100IUml
 1
penicillin, 10mgml
 1 streptomycin and 10% heat-inactivated foetal
calf serum as described (Duan et al, 2003). Culturing HepG2 cells
under polarising conditions was performed on the insert filters
(3.0mm, Corning BV, The Netherlands) as described previously
(Wu et al, 2004a). After culturing, the cells were scraped and
centrifuged by 3000r.c.f. at 41C for 10min. The pellets were lysed,
sonicated and centrifuged as described (Liu et al, 2002). The
activity of alk-SMase and the protein content were determined.
Amplification and cloning of alk-SMase cDNA from HepG2
cells HepG2 cells were suspended in RNAlater solution. Total
RNA was extracted by Total RNA Extraction kit (Amersham
Biosciences) and reversely transcripted to cDNA by a Thermo-
script RT–PCR System (Invitrogen). Alk-SMase cDNA was
amplified by PCR using sense primer 50tcggtaccgaaagcatgagagg
cccggccgtcctc30 and antisense primer 50tagcggccgcctgcgacctcaga
cagaagaat30 according to the cDNA sequence of alk-SMase gene
(GenBank AY230663) with the cDNAs as templates. The PCR
products were isolated by 1% agarose gel electrophoresis and each
band was purified by GFX DNA purification kit. The products were
digested with KpnI/NotI and constructed into KpnI and NotI sites
of pcDNA4/TO/myc-His plasmid. The cDNA inserts were
sequenced by Cybergene (Huddinge, Sweden) using sense 50cgc
aaatgggcggtaggcgtg30 and antisense 50tagaaggcacagtcgagg30primers
of the vector and an alk-SMase primer 50ggtggtgggacaacggca30
from the site 349–367, based on the gene sequence of human
alk-SMase (Duan et al, 2003) (GenBank AY230663).
Genomic alk-SMase DNA extraction and sequence The genomic
DNA of HepG2 cells was examined as described previously (Wu
et al, 2004a). The cells were lysed and the lysate were used as
template. The genomic DNA of alk-SMase gene from exon 3 to
exon 5 was amplified by PCR using sense 50cacggcatgacgaccg
tggacaaac30 and antisense 50tagcggccgcctgcgacctcagacagaagaat30
primers according to the genomic sequence of ENPP7 in GenBank
(NM_178543). The 2.6kb PCR product was sequenced by
Cybergene with sense 50cacggcatgacgaccgtggacaaac30 and 50gccttcc
actacgccaacaa30, and antisense 50tagcggccgcctgcgacctcagacagaagaa
t30, and 50tgcatgaggtgctcgtgaga30 primers.
Transient expression COS-7 cells, which do not express endo-
genous alk-SMase, were transfected with 4mg of the constructed
plasmids with the PCR products identified from HepG2 cells or the
clone AK126250 by the lipofectamine as described previously
(Duan et al, 2003). Control cells were transfected with the mock
plasmid in the same way as the transfected cells. The cells were
then cultured for 48h, scraped and lysed as described (Duan et al,
2003). The activities of alk-SMase in the cell-free extracts were
determined. The efficiency of the transfection was monitored by
either western blotting or the simultaneous transfection of Lac-Z
gene followed by b-galactosidase analysis.
Liver sample preparation For alk-SMase assay, human liver
biopsy samples were homogenised in 50mM Tris–HCl buffer
containing 2mM EDTA, 1mM PMSF, 1mM benzamidine, 0.5mM
dithiotheritol and 2.5mgml
 1 bile salts, followed by sonication for
10s. The sonicates were centrifuged at 10000r.c.f. for 10min and
the supernatants were saved for biochemical analysis.
Determination of SMase, galactosidase and proteins The activities
of acid, neutral and alk-SMase were determined as described, using
choline-labelled SM ([
14C-SM]) as substrate in different assay
buffers (Duan and Nilsson, 2000; Liu et al, 2006). The activity of
b-galactosidase in COS-7 cells after transfection was assayed by a
b-gal assay kit (Invitrogen), using ortho-nitrophenyl-b-galacto-
pyranoside as substrate (Wu et al, 2004a). The protein was
analysed by a kit from Bio-Rad (Sundbyberg, Sweden) using
bovine albumin as a standard.
Western blot Western blot for alk-SMase was performed as
described (Duan et al, 2003). In brief, the cell lysate containing
50mg cellular proteins was subjected to 10% SDS–polyacrylamide
gel electrophoresis and then transferred to a nitrocellulose
membrane electrophoretically. After blocking, the membrane was
probed with anti-human SMase antibody (1:2500) and then
reacted with rabbit IgG antibody (1:50000) conjugated with
horseradish peroxidase. The alk-SMase bands were identified by
ECL advanced reagents and the emitted light was recorded on
Kodak X-ray film. When necessary, the membranes were then
stripped and reprobed with anti-actin antibody as a loading
control.
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Expression of alk-SMase in HepG2 liver cancer cells
After RT–PCR in total RNA isolated from HepG2 liver cancer cells,
three products of 1.4, 1.2 and 0.4kb were identified by agarose gel
electrophoresis (Figure 1, upper panel). Each product was then
purified, cloned and sequenced. The results are shown in the lower
panel of Figure 1. The 1.4kb form turned out to be a wild-type
cDNA of alk-SMase, which contains five translated exons as
indicated. The 1.2kb form is a product with exon 4 truncated. The
0.4kb form is only a link of exons 1 and 5. Both 1.4 and 1.2kb
forms were then subcloned and transiently expressed in COS-7
cells. Expression of the 1.4kb cDNA demonstrated high alk-SMase
activity, whereas expression of the mutant 1.2kb form showed no
alk-SMase activity (Figure 2). The similar activity of b-galactosi-
dase in both cases (Figure 2, middle panel) as well as the Western
blot (Figure 2, bottom panel) confirms that the abolishment of
alk-SMase activity of 1.2kb was not caused by the insufficient
transfection.
To further address whether the formation of the 1.2kb form
is caused by genomic mutation, the genomic domain
between exons 3 and 5 in HepG2 cells was extracted by PCR and
sequenced. No mutation at genomic level was identified (data not
shown). The 1.2kb form was therefore caused by an alternative
splicing.
Since both wild-type and mutant alk-SMase mRNAs were
identified in HepG2 cells, the expression of the wild-type enzyme
in the cells was examined in both monolayer and polarised
conditions. As shown in Figure 3, the activity of alk-SMase was low
in monolayer cells and was maximal at about 80% confluence (6
days) and then declined when the culturing was continued.
However, in the cells cultured in polarised conditions, the alk-
SMase activity was significantly increased with the time. The
results indicate that the expression of the wild-type alk-SMase is
associated with differentiation.
How often the alternative 1.2kb mRNA occurs in different types
of liver cancer is unknown, since the answer to this question
requires studies of a large number of liver tumours, which are not
very common in Sweden. In a preliminary study, we performed
similar PCR using a cDNA template isolated from a hepatoma
tissue of a patient with autoimmune hepatitis. Two PCR products
with the size of 1.4 and 1.2kb were identified (Figure 4, upper left).
The two products were then purified, amplified by PCR (Figure 4,
lower left panel) and sequenced. We found that the 1.4kb is the
wild-type mRNA, whereas the 1.2kb is identical to that found in
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Figure 1 Identification of alk-SMase cDNA in HepG2 cells. Total RNA was extracted from HepG2 cells and alk-SMase cDNA was amplified by RT–PCR.
The PCR products were visualised by 1% agarose gel electrophoresis (upper panel). The lower panel shows the exons found in the PCR products based on
DNA sequence data. The black boxes indicate the translated exon and the order of the exon is indicated.
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Figure 2 Transient expression of the wild-type and the mutant form of
alk-SMase mRNA in COS-7 cells. The 1.4 and 1.2kb transcript found in
HepG2 cells were purified, cloned and constructed in pcDNA4/TO/myc-
His. After transfecting COS-7 cells for 48h culture, the cells were lysed and
the activities of alk-SMase (upper panel) and b-galactosidase (middle panel)
were determined. Western blot of the cell lysate for alk-SMase was
performed (bottom panel). Results for activity assay were mean±s.e.m.
from three separate experiments.
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Figure 3 Expression of alk-SMase in HepG2 cells. HepG2 cells were
cultured in both monolayer for 6 (80% confluence) and 15 days, and
in polarised conditions for 15, 18, 21 and 24 days. The cell-free extracts
were prepared and alk-SMase activity in the cell lysate was determined.
ML, monolayer; PL, polarised. The days of culturing were indicated. Results
are mean±s.e.m. form duplicate determinations in three separate
experiments.
AB
Figure 4 Identification of alk-SMase cDNA in one hepatoma tissue from
a patient with autoimmune hepatitis. The alk-SMase cDNA was amplified
by PCR using the total cDNA isolated from the tissue as a template. The
PCR products were visualised by 1% agarose electrophoresis (left panel).
The two PCR products were further purified and amplified by second PCR
(lower left panel). The difference in cDNA sequence is shown on the right
panel, which shows the absence of exon 4. (A) cDNA of wild-type alk-
SMase as a template. (B) cDNA of the hepatoma as a template. The two
arrows indicate the 1.4 and 1.2kb forms identified.
A
B
Figure 5 The amino-acid and cDNA sequences of AK126250 clone identified in liver tumour. The panel A shows the full length of amino-acid sequence
of AK126250. The underlined sequence indicates the N-terminal tag that links to the wild-type alk-SMase. The panel B displays part of the cDNA sequence
of AK126250. The start codon of the protein is in bold, and that of the wild-type alk-SMase is in bold and underlined.
Alkaline sphingomyelinase in liver tumours
Y Cheng et al
1444
British Journal of Cancer (2007) 97(10), 1441–1448 & 2007 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sHepG2 cells, without exon 4 (Figure 4, right panel). The results
indicate that the 1.2kb aberrant form can be identified in human
liver cancer tissue.
Expression of a ‘big’ alk-SMase in liver tumour
By FIS (full-length insert sequence) searching in the GenBank, we
found a cDNA clone (GenBank AK126250) with 2031bp that
encodes full length of alk-SMase plus a 73-amino-acid tag linked to
the N terminus of the enzyme (Figure 5, upper panel). The clone
for this ‘big’ alk-SMase was identified from a human liver tumour.
Looking at the genomic sequence, we found that the big alk-SMase
is translated by an alternative start codon, which is located
upstream of the wild-type mRNA of alk-SMase (Figure 5, lower
panel). To investigate whether this protein has alk-SMase activity,
the cDNA clone was purchased and expressed in COS-7 cells. As
shown in the box of Figure 6, the alk-SMase activity in the cells
transfected with AK126250 was three-fold higher than that in
control cells but still much lower than that in the cells transfected
with wild-type alk-SMase. Western blot clearly showed that the
AK126250 protein had been expressed to similar level as the wild-
type alk-SMase cDNA (Figure 6, lower panel). Since the N terminus
of wild-type alk-SMase contains a transmembrane domain that
serves as a signal peptide, TM-pred analysis was performed for
AK126250 protein. As shown in Figure 7, linking the 73 residues at
the N-terminal changes the hydrophobic feature of the enzyme.
The big alk-SMase no longer has a signal peptide at the N
terminus.
We also examined whether the big alk-SMase is expressed in
HepG2 cells by RT–PCR using new sense primer 50tcggta
ccgaaagcatgctcaagttgataccac30 and the wild-type antisense primer
according to the sequence of the big enzyme. No PCR product with
correct size was identified, indicating that this type of alk-SMase is
not expressed in HepG2 cells (data not shown).
Alk-SMase activity in liver diseases
For addressing a question whether alk-SMase activity is detectable
in human liver biopsies, three types of SMase were analysed in
30 biopsy samples. The results with the diagnosis are shown
in Table 1. The activity of alk-SMase was detectable in liver
biopsies and was high comparing with acid and neutral SMase.
Although not conclusive due to the number of the samples,
alk-SMase activity appeared particularly high in cholestatic liver
disease excluding primary sclerosing cholangitis (PSC)
(2.83±1.4nmolh
 1mg
 1) and low in steatosis (0.41±0.1nmol
h
 1mg
 1) and PSC (0.72±0.37nmolh
 1mg
 1). The activity did
not correlate with most biochemical examinations, except that a
positive correlation with a-antitrypsin was identified (r
2¼0.1658,
P¼0.0350).
DISCUSSION
Alk-SMase is specifically expressed in the intestinal tract and
human liver. The clinical implications of the enzyme in intestinal
tumours have been a topic under the last decade. The accumu-
lating evidence indicates that, in the intestinal tract, alk-SMase
may prevent colonic tumorigenesis. First, the enzyme generates
antiproliferative and proapoptotic lipid messenger ceramide
(Duan et al, 2003; Hertervig et al, 2003). Second, the enzyme
inhibits proliferation of human colon cancer cells (Hertervig et al,
2003). Third, the enzyme activity is reduced in both longstanding
ulcerative colitis and colonic tumorigenesis (Hertervig et al, 1997,
1999; Sjo ¨qvist et al, 2002). And finally, mutation has been
Alk-SMase activity (pmol h–1 mg–1) after transfection
Activity
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n
Figure 6 Expression of cDNA of wild-type alk-SMase and the
AK126250 in COS-7 cells. COS-7 cells were transfected with the wild-
type and AK126250 cDNA. The alk-SMase activities in the lysates 24h after
transfection were determined and the results are shown in the box of the
upper panel. The expressed wild-type alk-SMase and the AK126250
proteins were shown by Western blot in the lower panel. Lane 1: wild-type
alk-SMase expressed in COS-7 cells. Lanes 2 and 3: control COS-7 cells.
Lanes 4 and 5: AK126250 expressed in COS-7 cells. A loading control by
probing the membrane with anti-actin was shown below.
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Figure 7 Comparison of the TM-pred analysis of N-terminal transmem-
brane domains of wild-type alk-SMase and AK126250 protein. The X-axis is
the amino-acid sequences of the proteins and the Y-axis is the
hydrophobicity of the amino-acid residues.
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activity (Wu et al, 2004a).
Human liver is the only organ except the intestine that expresses
alk-SMase. It is both a site of primary tumours and the most
common site of colon cancer metastasis. It is well-known that PSC
increases the risk of hepatobiliary cancer (Yang et al, 2001; Ohata
et al, 2003; Lazaridis and Gores, 2006) as well as colon cancer
associated with colitis (Broome and Bergquist, 2006). The disease
is treated with ursodeoxycholic acid to decrease the risk of
colorectal cancer (Pardi et al, 2003) and ursodeoxycholic acid has
been shown to induce expression alk-SMase in both animal models
and cell culture studies (Cheng et al, 1999; Liu et al, 2006). We
therefore raised a question whether this ectoenzyme may also be
an antitumour factor both in development of primary hepatic and
biliary carcinomas and in the regulation of metastatic tumour
growth. To answer the question, it is important to study the
expression of the enzyme associated with liver cancer and
precancerous diseases.
In this study, we showed that HepG2 liver cancer cells have both
wild-type (1.4kb) and mutant forms (1.2 and 0.4kb) of alk-SMase
transcript. The identification of the 1.2kb form may have special
importance, because it is an inactive form and it resembles the
mutation previously identified in HT29 colon cancer cells (Wu
et al, 2004a). Although the mutations found in HepG2 and HT29
cells are not identical, both mutations involve a deletion of exon 4.
We previously showed that the amino acid His at 353 position in
exon 4 is critical for the enzyme function, and site mutation of
H353 abolishes the enzyme activity (Wu et al, 2004a). H353 in fact
participates in the formation of two metal coordinate sites, and
recent studies showed that metal ion sites in NPP family may play
important roles in substrate binding (Zalatan et al, 2006). It is
therefore expected that the protein encoded by the 1.2kb form
showed no alk-SMase activity. The similar exon 4 deletion in both
liver and colon cancer cells casts light on the close link of colon
and liver in tumorigenesis. Unlike HT29 colon cancer cells, HepG2
cells also express the wild-type alk-SMase. The expression rate is
low under monolayer conditions, but increased when the cells are
under polarising, that is, differentiating conditions. The finding is
in agreement with our previous study on Caco-2 cells (Wu et al,
2004a). Thus, the factors that inhibit the differentiation of liver
cells may suppress the expression of alk-SMase.
The present study also characterised another form of alk-SMase
registered in GenBank, which was identified in a liver tumour. The
cDNA clone encodes the full length of the enzyme plus 73-amino-
acid residues linking to the N terminus. It is translated from an
alternative starting codon upstream of the wild-type mRNA.
Although transient expression showed some activity of the big alk-
SMase, but the activity was much lower than the wild-type enzyme.
The reduction may be caused by the change of the hydrophobicity
of alk-SMase at the N terminus, leading to loss of a signal peptide,
which regulates the traffic of the enzyme to endoplasmic reticulum
for glycosylation and to the plasma membrane for secretion (Wu
et al, 2005b). Without the signal peptide, the enzyme may not be
properly transported and glycosylated. Normal transportation and
glycosylation are important factors for full activity of the enzyme
(Wu et al, 2005b).
By measuring acid, neutral and alkaline SMase activities in
human liver biopsy samples, we showed that alk-SMase activity is
detectable in human liver biopsies. The activity is high and at least
equal to that of acid SMase, which is known to be highly expressed
in the liver (Spence et al, 1979). The biopsy samples examined
were taken from patients with different liver diseases. The number
of observations was too small to conclusively identify differences
in alk-SMase expression among different diseases. However,
relatively low activities were indicated in steatosis and PSC, which
increases risk for hepatocellular carcinoma (Yang et al, 2001;
Table 1 SMase activity (nmolh
 1mg
 1) in liver biopsy samples
Patient Age (years) Sex A-SMase N-SMase Alk-SMase Diagnosis
1 70 F 2.253 1.574 2.143 Cholestatic, not PBC
2 72 M 4.412 3.462 5.527 Cholestatic, not PBC
3 64 F 1.136 1.013 0.824 Cholestatic, not PBC
4 30 M 1.293 2.174 0.308 Steatosis
5 73 M 1.105 1.571 0.745 Steatosis
6 69 M 0.825 0.316 0.431 Steatosis
7 60 M 0.837 0.375 0.439 Steatosis
8 67 M 1.356 0.389 0.105 Steatosis, mild hepatitis
9 63 F 1.926 1.181 1.415 PSC
10 31 M 0.758 0.657 0.562 PSC
11 42 M 1.009 1.582 0.174 PSC
12 47 M 0.621 0.897 1.093 NASH
13 74 M 2.372 1.015 1.120 NASH
14 72 F 1.941 2.921 4.586 Toxic, including drug not alcohol
15 79 F 1.982 1.690 1.817 Toxic, including drug not alcohol
16 73 F 1.379 0.964 1.249 PBC
17 74 F 0.883 1.296 1.593 PBC
18 85 M 2.511 1.246 1.778 Cryptogenic cirrhosis
19 83 M 1.310 1.818 2.039 Cryptogenic cirrhosis
20 65 M 1.122 0.396 0.456 Cryptogenic hepatitis
21 53 F 0.860 0.776 0.862 Alcoholic cirrhosis
22 54 F 2.768 1.387 2.011 Alcoholic cirrhosis
23 69 F 0.977 2.570 3.633 Alcoholic hepatitis
24 33 M 0.957 1.000 1.378 Autoimmune hepatitis
25 25 F 1.258 0.851 0.439 Autoimmune hepatitis
26 41 F 0.339 0.574 0.513 Haemochromatosis
27 50 M 0.772 0.413 0.418 Haemochromatosis
28 37 M 0.754 0.541 0.424 Chronic hepatitis C
29 51 F 0.750 1.519 2.189 Viral infection
30 90 F 1.155 0.551 0.448 Systemic disease
A-SMase¼acid sphingomyelinase; Alk-SMase¼alkaline sphingomyelinase; F¼female; M¼male; PBS¼primary biliary cirrhosis; PSC¼primary sclerosing cholangitis;
NASH¼non-alcoholic steatohepatitis; N-SMase¼neutral sphingomyelinase.
Alkaline sphingomyelinase in liver tumours
Y Cheng et al
1446
British Journal of Cancer (2007) 97(10), 1441–1448 & 2007 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sOhata et al, 2003) and cholangiocarcinoma (Lazaridis and Gores,
2006), respectively. The finding may indicate an early reduction of
the enzyme activity in precancerous diseases in the liver. Alk-
SMase activity in general did not significantly correlate with many
of the routine liver tests, but positively with the level of a-
antitrypsin. The significance of this finding is unknown. Since liver
cells express trypsin-like protein (Leytus et al, 1988) and trypsin
has been shown to dissociate alk-SMase from the intestinal mucosa
(Wu et al, 2004b), anti-trypsin may prevent alk-SMase from release
and thus increase its levels.
By examining a cDNA sample isolated from a biopsy of
hepatocellular carcinoma, we did find similar coexistence of 1.4
and 1.2kb mRNA of alk-SMase in the tissue, indicating that such
mutation does occur in human liver cancer tissues. So far we have,
however, not had access to enough human liver tumours to provide
data on the frequency of different alk-SMase mutations in such
tumours. Obviously this is an important issue for further studies.
In conclusion, our results identified mutations of alk-SMase
in liver tumorigenesis, resulting in significant reduction of the
enzyme activity. The identification of similar deletion of exon 4 in
colon and liver cancers may give insight into the frequent liver
metastasis of colon cancer. Further investigations with larger
number of tissue samples should focus on type and frequency of
the mutations and their pathological implications in both cancer
and precancerous liver diseases.
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